• Vaccine Name: B. pertussis FhaB and 69 kDa OMP protein vaccine
• Target Pathogen: Bordetella pertussis
• Target Disease: Whooping Cough
• Vaccine Ontology ID: VO_0011498
• Type: Subunit vaccine
• Status: Research
• Antigen: Combination of the B. pertussis 69-kDa outer membrane protein and filamentous hemagglutinin (fhaB)
• fhaB gene engineering:
  • Type: Recombinant protein preparation
  • Description: A crystal clear supernatant of 5-day-old static cultures containing proteolysis inhibitor was purified. To remove impurities, the FHA was precipitated by overnight dialysis against 25-30 volumes of buffer A at 4 C, and the precipitate was collected by centrifugation. The precipitated FHA was dissolved in the smallest possible volume of 40 mM B-alanine buffer at pH 3.5, clarified by centrifugation, and applied at room temperature at a flow of 30 ml/h to a Superose 12 column. The retained highly purified FHA was eluted (Novotny et al., 1991).
  • Detailed Gene Information: Click Here.
• Adjuvant: Alhydrogel vaccine adjuvant
  • Adjuvant name: Alhydrogel vaccine adjuvant
  • VO adjuvant ID: VO_0001241
  • Description: 4.0 ml Alhydrogel (Novotny et al., 1991).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: Groups of mice were injected intraperitoneally with 0.5 ml volumes of four concentrations (Novotny et al., 1991).
• Challenge Protocol: Mice were challenged intracerebrally 14 days after antigen injection. The challenge dose contained 300-400 LD50, and a 1:1250 dilution of the challenge does contained ~ 10cfu. All mice were challenged within 90 minutes after the challenge suspension was thawed; the challenge was injected using a 1 ml syringe in a Hamilton PB600-I dispensor that reproducibly delivers 20-ul voumes (Novotny et al., 1991).
• Efficacy: A combination of the 69-kDa outer membrane protein and filamentous hemagglutinin (fhaB), both isolated from lymphocytosis promoting factor (LPF; pertussis toxin) minus mutants of Bordetella pertussis, is protective in the mouse intracerebral challenge potency (Kendrick) test (Novotny et al., 1991).